Apogee's lead asset zumilokibart achieved strong Phase two results in atopic dermatitis, with roughly two-thirds of patients reaching significant skin clearance at 16 weeks. The drug targets IL-13, a key driver of type two inflammation. What sets zumilokibart apart is its half-life extension, enabling quarterly or even twice-yearly maintenance dosing. Most atopic dermatitis patients don't achieve simultaneous itch and skin improvement with current treatments, the company says. The extended dosing schedule addresses a gap in convenience that existing therapies haven't filled

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

Apogee's lead asset zumilokibart achieved strong Phase two results in atopic dermatitis, with roughly two-thirds of patients reaching significant skin clearance at 16 weeks. The drug targets IL-13, a key driver of type two inflammation. What sets zumilokibart apart is its half-life extension, enabling quarterly or even twice-yearly maintenance dosing. Most atopic dermatitis patients don't achieve simultaneous itch and skin improvement with current treatments, the company says. The extended dosing schedule addresses a gap in convenience that existing therapies haven't filled

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

June 22, 2026 07:45 ET (11:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.